Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections. With over 100 years of experience, Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDFs) to the pharmaceutical industry.
The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in North America, Europe and Asia, and currently employs over 1500 people.
Since July 2013, Xellia Pharmaceuticals has been wholly owned by Novo Holdings A/S, the holding Company of the Novo Group.
Learn more on www.xellia.com